RDGL.US Vivos Inc
- Market cap
- USD 20.8M
- P/E
- -
- P/B
- 7.56x
- ROE
- -146.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is RDGL.US undervalued?
Graham numberThe Graham number of Vivos Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Vivos Inc fundamental analysis
No fundamental analysis for Vivos Inc yet.
Vivos Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Vivos Inc
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; Precis…
Full company profileVivos Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Vivos Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.11K | 4.05K | 0.00 | 9.50K | 7.00K | 14.9K | 36.5K | 19.5K | 28.0K | 68.4K | 145K |
| Gross Profit | 8.11K | 4.05K | 0.00 | 3.47K | 1.39K | 2.89K | 7.72K | -6.04K | -2.98K | -59.8K | -19.5K |
| Operating Income | -4.44M | -2.62M | -2.47M | -1.33M | -673K | -2.50M | -2.52M | -2.79M | -2.60M | -3.17M | -2.40M |
| EBITDA | - | -2.51M | -2.05M | -1.35M | -670K | -2.50M | -2.47M | -2.79M | -2.60M | -3.16M | -2.34M |
| Net Income | -9.85M | -6.42M | -7.70M | -1.61M | -957K | -2.53M | -2.47M | -2.89M | -2.91M | -3.07M | -4.03M |
| EPS | - | -0.78 | -0.05 | -0.01 | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 42.0K | 15.7K | 16.5K | 43.9K | 938K | 1.63M | 1.74M | 1.61M | 2.23M | 1.87M | 2.88M |
| Total Liabilities | 17.2M | 4.28M | 959K | 1.52M | 906K | 167K | 81.7K | 245K | 86.2K | 207K | 124K |
| Shareholders' Equity | -17.2M | -4.26M | -942K | -1.48M | 32.0K | 1.47M | 1.66M | 1.37M | 2.15M | 1.66M | 2.76M |
| Cash & Short-term Investments | 27.9K | 8.32K | 5.49K | 20.4K | 904K | 1.61M | 1.71M | 1.59M | 2.21M | 1.56M | 2.34M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.93M | -1.29M | -700K | -837K | -876K | -964K | -1.12M | -1.29M | -1.68M | -2.06M | -2.34M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 103K | 491K |
| Free Cash Flow | - | -1.29M | -700K | -837K | -876K | -964K | -1.12M | -1.29M | -1.68M | -2.16M | -2.83M |
| Ratios | |||||||||||
| ROE | - | - | - | - | -2,987.4% | -172.3% | -148.7% | -212.1% | -135.5% | -184.6% | -146.2% |
| ROA | -23,466.3% | -40,891.4% | -46,723.6% | -3,669.9% | -102.1% | -154.7% | -141.7% | -179.8% | -130.3% | -164.2% | -140.0% |
| Net Profit Margin | -121,545.3% | -158,330.7% | - | -16,948.4% | -13,671.3% | -16,979.7% | -6,767.7% | -14,844.9% | -10,396.3% | -4,483.9% | -2,780.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Vivos Inc dividends
Vivos Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:8 on Jun 28, 2019.
Who owns Vivos Inc
- Insiders 3.35%
- Institutions 0.00%
- Public & others 96.65%
- Shares outstanding 514M
- Free float 472M
Vivos Inc company profile
- Company name
- Vivos Inc
- Ticker
- RDGL.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1
- Fiscal year end
- December
- Address
- 1030 N Center Parkway, Kennewick, WA, United States, 99352
- Phone
- 509 222 2222
- Website
- radiogel.com
About Vivos Inc
Vivos Inc., a radiation oncology medical device company, engages in the development of yttrium-90-based precision radionuclide therapy devices for the treatment of non-resectable tumors in the United States. The company develops RadioGel, which is an injectable particle-gel for Precision Radionuclide Therapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. It is also developing PLGA-g-PEG polymers; PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents; Duncan Chiller, a general laboratory equipment for non-water localized chilling; and other products under the Alpha-Gel, Beta-Gel, Gamma-Gel, and Peltier Chiller brands. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Kennewick, Washington.
Vivos Inc management
5- Dr. Michael K. Korenko Ph.D.CEO, President & Director · born 1946
- Mr. Brad Allan WeeksPresident · born 1982
- Dr. David J. Swanberg M.S., P.E.Chief Operating Officer · born 1957
- Dr. Carlton M. Cadwell D.D.S.Independent Chairman & Secretary · born 1945
- Dr. Jim DuncanChief Technology Manager